Deltex Medical Group plc
AGM 28 April 2011
Ewan Phillips
Introduction
• World leader in ODM
• Intervene – fluid during surgery
• Monitor – cardiac output in critical care
• Simple – to learn, to use & very safe
• Evidence – robust: clinical & economic
• Implementation
• Bottom-up – hospital level by procedure
• Top-down – system level standard of care
• Sales growing
• Fastest growth in surgery in UK & US
• High margins
• 74% overall
• >80% in direct markets
• Stable cost base
• Cash positive in second half
Financial Highlights - Cash
NICE guidance
•
•
•
•
Important validation
Positive recommendation for surgery
Reduce post-operative complications
Reduce cost by circa £1,100 per patient
• Major and high risk surgery
• Over 800,000 NHS patients a year
• “Dominant” technology
• Still need change in practice and NHS cash
• £20 billion savings target
• Innovative Technologies Adoption Procurement Programme
• National Technology Adoption Centre support
• Enhanced recovery – national roll-out
• NICE evaluation pathway
• Issued 30 March
• Product specific
• Extra income for NHS hospitals under CQUIN
• Oesophageal Doppler specific
• Enhanced recovery
International growth strategy
• US Strategy
•
•
•
•
Demonstration ‘stories’ from existing accounts
Stand-alone improvement & enhanced recovery
Targeting hospital groupings with ‘quality’ agendas
Quality indicator for surgery
• International Strategy
• Build on Paris tender in France
• Support Spanish projects to conclusions
• ‘Exporting’ NICE, NTAC, CQUIN, enhanced recovery
• ODM solves a major clinical problem
• ODM implementable:
• Stand-alone change in practice
• Enhanced recovery surgical programmes
•
•
•
•
Evidence key to system wide adoption
NICE guidance is important validation
Growth rates encouraging
Potential for considerable acceleration